Bursa Malaysia’s initial public offering market is on course for its strongest year in over a decade, driven by a healthcare blockbuster already completed, a front-end semiconductor listing scheduled for May 20, and a pipeline that includes one of the country’s most anticipated real estate and pharmaceutical listings in years.
Data compiled by Bloomberg shows Malaysian IPOs raised US$1.2 billion in the first four months of 2026, already approaching the US$1.4 billion total for the full year of 2025. If SkyeChip Bhd and the proposed IOI Properties Group Bhd REIT both proceed as planned, 2026 full-year proceeds would reach approximately US$1.8 billion, the highest annual figure for Bursa Malaysia since 2013.
Key Facts At A Glance
- Malaysian IPOs raised US$1.2 billion (RM4.71 billion) in the first four months of 2026, nearing the US$1.4 billion recorded for the full year of 2025
- Sunway Healthcare Holdings Bhd raised RM2.86 billion in Malaysia’s largest offering in nine years; shares jumped more than 38 percent on debut
- SkyeChip Bhd, a Penang-based fabless IC design company, is raising RM352 million in its Main Market IPO, with listing scheduled for May 20, 2026
- IOI Properties Group Bhd is targeting a RM1.98 billion REIT IPO for Q4 2026, backed by a RM7.58 billion portfolio of retail, hotel, and office assets
- SkyeChip and IOI REIT combined would push 2026 proceeds to US$1.8 billion, the highest since 2013, per Bloomberg data
- Big Caring Group, a Creador-backed pharmaceutical chain, is seeking a valuation of RM20 billion that could make it the year’s largest listing
- KK Mart Retail Bhd has filed a draft prospectus and is among the additional issuers in the pipeline
- Over 60 percent of SkyeChip’s IPO proceeds, or RM211.5 million, are earmarked for research and development
- 22 cornerstone investors committed to SkyeChip’s institutional offering, including the Employees Provident Fund Board and AIA
The Year’s First Blockbuster
Sunway Healthcare Holdings Bhd established the benchmark for 2026 when it raised RM2.86 billion in its March listing, the largest initial public offering in Malaysia in nine years. Shares opened at the IPO price of RM1.45 and climbed to as high as RM2.01 on debut day, a gain of more than 38 percent, placing the company’s market capitalisation at approximately RM23 billion. The healthcare offering confirmed what market participants had been signaling: that institutional and retail demand for well-structured, sector-leading issuers remained robust despite a mixed global environment.
SkyeChip: A Front-End Semiconductor Debut
SkyeChip Bhd’s listing on May 20 is being closely watched as the largest front-end semiconductor IPO in Southeast Asia. The Penang-based company specialises in integrated circuit design and silicon intellectual property, developing licensable IP blocks such as high bandwidth memory interfaces and die-to-die interconnects, which are integrated into customers’ chips, as well as custom application-specific integrated circuits. This places SkyeChip at the higher-value end of Malaysia’s semiconductor supply chain, distinct from the back-end outsourced semiconductor assembly and test operations that have historically dominated the sector’s public market presence.
The IPO comprises 400 million new shares at an indicative price of RM0.88 each, raising RM352 million entirely through new share issuance, with no offer for sale by existing shareholders. More than 60 percent of the proceeds, or RM211.5 million, will be channelled into research and development, with further allocations for advanced packaging capabilities and compute and AI silicon products. The retail offering attracted strong institutional support, with 22 cornerstone investors, including the Employees Provident Fund Board, Lembaga Tabung Angkatan Tentera, AIA, and AHAM Asset Management, committing to approximately 60 percent of the institutional offering. Maybank Investment Bank Bhd and CIMB Investment Bank Bhd are joint bookrunners and underwriters.
Analyst fair value estimates at the time of prospectus launch ranged from 99 sen (Mercury Securities) to RM1.68 per share (PublicInvest Research), implying upsides ranging from 12.5 to 90.9 percent against the RM0.88 IPO price. All three research houses noted SkyeChip’s positioning in the high-margin IP licensing segment, but differed on appropriate earnings multiples, with applied price-earnings ratios ranging from 40 to 45 times. SkyeChip held an unbilled order book of approximately RM130.3 million as at March 31, 2026, and reported a revenue compound annual growth rate of 44.6 percent in recent financial years.
IOI Properties’ REIT And The Q4 Pipeline
IOI Properties Group Bhd announced in April 2026 plans to establish IOIPG Malaysia REIT, targeting a listing on the Main Market of Bursa Malaysia in Q4 2026. The portfolio of assets proposed for injection is valued at RM7.58 billion and includes IOI City Mall, six hotel properties including W Kuala Lumpur and Le Meridien Putrajaya, and office assets such as IOI City Towers. The IPO is targeting proceeds of approximately RM1.98 billion. The REIT structure is designed to reduce the group’s net gearing, with analysts estimating a decline from 89.6 percent to approximately 68.8 percent, while unlocking capital for redeployment into development activities.
Beyond the REIT, two further issuers are advancing through the regulatory pipeline. Big Caring Group, a Creador-backed pharmaceutical retail chain, has filed a draft prospectus and is seeking a valuation of approximately RM20 billion, which, if achieved, would make it the year’s largest Bursa listing, surpassing Sunway Healthcare. KK Mart Retail Bhd, a convenience store chain, has also filed a draft prospectus.
Structural Drivers Behind The Surge
Raymond Chooi, Maybank Investment Bank’s regional head of equity capital markets, attributed the momentum to a combination of post-pandemic recovery in corporate earnings, government policy impact in strategic sectors, and the pull of the global AI investment cycle. Malaysia’s national energy transition roadmap and its semiconductor industry roadmap are being cited by issuers and bankers as catalysts that have translated into earnings visibility, improving the case for public listings. Yen Voo, JPMorgan’s head of Malaysia equity research, noted that recent listings indicate that issuers with credible growth visibility and institutional backing can attract institutional demand even in a selective global market for new equity.